FDA Expanded Access Program

FDA Expanded Access Program
Name	FDA Expanded Access Program
Established	1987
Jurisdiction	United States
Parent agency	Food and Drug Administration

FDA Expanded Access Program

The FDA Expanded Access Program provides a mechanism for patients to request access to investigational drugs, biologics, and medical devices outside of Food and Drug Administration-approved clinical trials. The program interfaces with stakeholders including pharmaceutical companies, academic medical centers such as Mayo Clinic, regulatory bodies like the National Institutes of Health, patient advocacy groups including American Cancer Society and individual clinicians at institutions such as Massachusetts General Hospital. It operates within a legal and policy framework shaped by statutes like the Food, Drug, and Cosmetic Act and executive actions tied to public health emergencies such as the 2009 swine flu pandemic.

Overview

The program is administered by the Food and Drug Administration through its Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, coordinating with sponsors such as Pfizer, Merck & Co., and biotechnology firms like Genentech. Requests are evaluated by FDA reviewers, institutional review boards at centers including Johns Hopkins Hospital, and treating physicians affiliated with universities such as Stanford University. Expanded access intersects with legislative milestones including the FD&C Act Amendments and advocacy campaigns by organizations like PatientsLikeMe and Cystic Fibrosis Foundation that have influenced access policies.

Eligibility and Application Process

Patients typically must have a serious or life-threatening condition, have exhausted available Clinical trial options at centers like MD Anderson Cancer Center or Dana-Farber Cancer Institute, and be ineligible for trials sponsored by entities such as Amgen or Gilead Sciences. Treating physicians submit an application to the Food and Drug Administration including clinical rationale, supporting documents from institutional review boards at hospitals like Cleveland Clinic, and informed consent modeled on templates used by American Medical Association affiliates. Sponsors must provide concurrence, often negotiated with corporate legal teams from firms such as Johnson & Johnson or small biotech startups backed by venture capital firms in Silicon Valley. For emergency situations, pathways mirror procedures used in public health responses by Centers for Disease Control and Prevention and may invoke expedited review mechanisms similar to those deployed during the Ebola virus epidemic.

Types of Expanded Access and Authorization Pathways

Pathways include single-patient access utilized at trauma centers like Bellevue Hospital, intermediate-size patient populations coordinated by consortia such as Translational Research Institute, and widespread treatment protocols resembling compassionate use programs run by multinational firms like Roche. Authorization mechanisms draw on precedents from emergency use during outbreaks such as the Zika virus outbreak and align with regulatory frameworks referenced in rulings by courts like the U.S. Court of Appeals for the D.C. Circuit. The program differentiates individual patient INDs from treatment INDs that mirror expanded programs used historically by companies like Bayer and Novartis.

Safety, Ethical, and Regulatory Considerations

Safety oversight involves pharmacovigilance systems akin to those used by World Health Organization and reporting obligations similar to adverse event surveillance used by European Medicines Agency. Ethical review by institutional review boards engages bioethicists from institutions such as Georgetown University and adheres to principles discussed in commissions like the Belmont Report. Sponsors weigh risks and benefits in light of case law such as decisions from the Supreme Court of the United States on medical liability, and policies shaped by advocacy from groups like Union for Ethical Biotrade. Conflicts can arise between corporate access policies at firms like Eli Lilly and Company and patient advocacy organizations, prompting discussion in forums including National Academies of Sciences, Engineering, and Medicine.

Program History and Notable Use Cases

The program evolved from early compassionate use cases in the 1980s amid the HIV/AIDS epidemic, where activists from groups such as ACT UP influenced policy at the Food and Drug Administration. High-profile instances include expanded access to antiviral agents during the 1996 antiretroviral rollout and oncology agents provided under protocols by institutions such as MD Anderson Cancer Center and companies like Celgene. Emergency use instances during the 2003 SARS outbreak and later the COVID-19 pandemic involved coordination between Operation Warp Speed, biotech firms like Moderna, and federal agencies including the Department of Health and Human Services. Judicial and legislative attention has come through cases and hearings involving members of United States Congress and oversight by committees such as the Senate Committee on Health, Education, Labor, and Pensions.

Impact on Drug Development and Policy debates

Expanded access affects clinical development strategies used by sponsors like GlaxoSmithKline and venture-backed startups, influencing trial enrollment at sites such as University of California, San Francisco and investment decisions by firms in NASDAQ. Critics argue expanded access complicates randomized controlled trial recruitment, a concern raised in academic journals published by presses like Elsevier and Nature Publishing Group, while proponents cite patient autonomy promoted by advocacy groups such as Fight Colorectal Cancer. Policy debates have prompted guidance documents from the Food and Drug Administration and recommendations from expert panels convened by institutions like Harvard Medical School. Ongoing legislative proposals in the United States Congress continue to shape access, balancing innovation incentives championed by industry trade groups like PhRMA against public-interest arguments advanced by charities such as The Leukemia & Lymphoma Society.

Category:Food and Drug Administration